AbbVie Inc.ABBVNYSE
Loading
Cash Flow PerformanceStable
Percentile Rank71
3Y CAGR-9.8%
5Y CAGR+1.2%
Year-over-Year Change
Operating cash flow minus capital expenditures
3Y CAGR
-9.8%/yr
vs +17.3%/yr prior
5Y CAGR
+1.2%/yr
Recent deceleration
Acceleration
-27.1pp
Decelerating
Percentile
P71
Within normal range
vs 5Y Ago
1.1x
Modest growth
Streak
3 yr
Consecutive declineStable
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $17.82B | -0.1% |
| 2024 | $17.83B | -19.2% |
| 2023 | $22.06B | -9.0% |
| 2022 | $24.25B | +10.3% |
| 2021 | $21.99B | +31.0% |
| 2020 | $16.79B | +31.5% |
| 2019 | $12.77B | -0.1% |
| 2018 | $12.79B | +35.6% |
| 2017 | $9.43B | +43.7% |
| 2016 | $6.56B | - |